PacBio's fourth quarter 2024 results showed a revenue of $39.2 million, a 33% decrease year-over-year. Despite this, the company reported a net income of $3.6 million, a significant improvement from a net loss of $82.0 million in the prior-year period, primarily due to a $154.4 million gain on debt restructuring. Operating expenses increased substantially due to preliminary non-cash impairment charges.
Revenue decreased by 33% year-over-year to $39.2 million in Q4 2024.
Net income significantly improved to $3.6 million in Q4 2024, primarily due to a $154.4 million gain on debt restructuring.
Operating expenses increased to $161.9 million, largely due to $90.1 million in preliminary non-cash impairment charges.
The company launched its Vega benchtop sequencing platform and SPRQ chemistry, aiming to expand access to HiFi long-read sequencing and improve cost efficiency.
PacBio anticipates returning to growth and expanding market share in 2025, leveraging its new Vega benchtop platform and SPRQ chemistry, despite ongoing macroeconomic uncertainties.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance